New drug trial aims to clear Alzheimer's-Linked brain plaques in down syndrome
NCT ID NCT06911944
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 26 times
Summary
This study tests whether donanemab can safely reduce amyloid plaques in the brains of adults with Down syndrome, who are at high risk for Alzheimer's disease. Sixty participants aged 35-50 will receive either donanemab or a placebo every 4 weeks for 12 months, followed by a 12-month extension where all receive the drug. The main goals are to measure amyloid reduction and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.